Free Trial
→ Stranded On The Flood Plains of History (From Porter & Company) (Ad)tc pixel Free BIO Stock Alerts

Bio-Rad Laboratories (BIO) Competitors

Bio-Rad Laboratories logo
$291.62 -5.55 (-1.87%)
Closing price 03:59 PM Eastern
Extended Trading
$285.60 -6.03 (-2.07%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BIO vs. RGEN, TECH, A, AMN, and BIO.B

Should you buy Bio-Rad Laboratories stock or one of its competitors? MarketBeat compares Bio-Rad Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Rad Laboratories include Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), AMN Healthcare Services (AMN), and Bio-Rad Laboratories (BIO.B). These companies are all part of the "medical" sector.

How does Bio-Rad Laboratories compare to Repligen?

Repligen (NASDAQ:RGEN) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Repligen has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Repligen has a net margin of 6.73% compared to Bio-Rad Laboratories' net margin of 6.52%. Repligen's return on equity of 4.88% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Repligen6.73% 4.88% 3.48%
Bio-Rad Laboratories 6.52%3.56%2.49%

In the previous week, Repligen had 4 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 4 mentions for Repligen and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.58 beat Repligen's score of 0.58 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
Repligen Positive
Bio-Rad Laboratories Positive

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$738.26M9.99$48.89M$0.90145.29
Bio-Rad Laboratories$2.58B3.02$759.90M$6.0748.04

97.6% of Repligen shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Repligen presently has a consensus price target of $164.64, suggesting a potential upside of 25.91%. Bio-Rad Laboratories has a consensus price target of $303.33, suggesting a potential upside of 4.01%. Given Repligen's stronger consensus rating and higher possible upside, equities analysts plainly believe Repligen is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.88
Bio-Rad Laboratories
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Repligen beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bio-Techne has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Bio-Techne presently has a consensus price target of $65.17, indicating a potential upside of 24.13%. Bio-Rad Laboratories has a consensus price target of $303.33, indicating a potential upside of 4.01%. Given Bio-Techne's stronger consensus rating and higher probable upside, equities research analysts plainly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Techne
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.71
Bio-Rad Laboratories
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Bio-Techne has a net margin of 9.05% compared to Bio-Rad Laboratories' net margin of 6.52%. Bio-Techne's return on equity of 13.57% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Techne9.05% 13.57% 10.66%
Bio-Rad Laboratories 6.52%3.56%2.49%

In the previous week, Bio-Techne had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 6 mentions for Bio-Techne and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.58 beat Bio-Techne's score of 0.06 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Techne Neutral
Bio-Rad Laboratories Positive

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$1.22B6.74$73.40M$0.6976.09
Bio-Rad Laboratories$2.58B3.02$759.90M$6.0748.04

Summary

Bio-Techne beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Agilent Technologies has higher revenue and earnings than Bio-Rad Laboratories. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$6.95B5.36$1.30B$4.9826.48
Bio-Rad Laboratories$2.58B3.02$759.90M$6.0748.04

65.2% of Bio-Rad Laboratories shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Agilent Technologies has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Agilent Technologies has a net margin of 19.55% compared to Bio-Rad Laboratories' net margin of 6.52%. Agilent Technologies' return on equity of 24.33% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Agilent Technologies19.55% 24.33% 12.99%
Bio-Rad Laboratories 6.52%3.56%2.49%

In the previous week, Agilent Technologies had 15 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 15 mentions for Agilent Technologies and 0 mentions for Bio-Rad Laboratories. Agilent Technologies' average media sentiment score of 0.69 beat Bio-Rad Laboratories' score of 0.58 indicating that Agilent Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Agilent Technologies Positive
Bio-Rad Laboratories Positive

Agilent Technologies presently has a consensus target price of $161.71, suggesting a potential upside of 22.63%. Bio-Rad Laboratories has a consensus target price of $303.33, suggesting a potential upside of 4.01%. Given Agilent Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe Agilent Technologies is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agilent Technologies
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.94
Bio-Rad Laboratories
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Agilent Technologies beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Bio-Rad Laboratories (NYSE:BIO) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Bio-Rad Laboratories has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Bio-Rad Laboratories currently has a consensus price target of $303.33, indicating a potential upside of 4.01%. AMN Healthcare Services has a consensus price target of $25.29, indicating a potential downside of 14.18%. Given Bio-Rad Laboratories' higher possible upside, equities analysts clearly believe Bio-Rad Laboratories is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
AMN Healthcare Services
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22

Bio-Rad Laboratories has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.02$759.90M$6.0748.04
AMN Healthcare Services$2.73B0.42-$95.70M-$0.87N/A

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, AMN Healthcare Services had 12 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 12 mentions for AMN Healthcare Services and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.58 beat AMN Healthcare Services' score of 0.26 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company Overall Sentiment
Bio-Rad Laboratories Positive
AMN Healthcare Services Neutral

Bio-Rad Laboratories has a net margin of 6.52% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
AMN Healthcare Services -0.95%18.01%5.19%

Summary

Bio-Rad Laboratories beats AMN Healthcare Services on 9 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO.B) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bio-Rad Laboratories has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

In the previous week, Bio-Rad Laboratories' average media sentiment score of 0.58 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Bio-Rad Laboratories Positive

Bio-Rad Laboratories has a consensus target price of $303.33, indicating a potential upside of 4.01%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bio-Rad Laboratories
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.15$759.90M$6.0750.11
Bio-Rad Laboratories$2.58B3.02$759.90M$6.0748.04

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Bio-Rad Laboratories 6.52%3.56%2.49%

Summary

Bio-Rad Laboratories beats Bio-Rad Laboratories on 7 of the 9 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO vs. The Competition

Export
MetricBio-Rad LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$7.80B$8.16B$6.43B$22.82B
Dividend YieldN/A2.51%2.67%4.11%
P/E Ratio48.0416.1024.4630.13
Price / Sales3.026.75500.5021.00
Price / Cash29.0717.1542.3623.85
Price / Book1.063.5410.434.59
Net Income$759.90M$225.32M$3.56B$1.07B
7 Day Performance-4.22%-0.12%-1.39%-0.60%
1 Month Performance14.65%1.43%0.86%-1.14%
1 Year Performance26.60%-4.31%19.42%18.94%

Bio-Rad Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO
Bio-Rad Laboratories
1.1862 of 5 stars		$291.63
-1.9%		$303.33
+4.0%		+31.5%$7.80B$2.58B48.047,450
RGEN
Repligen
3.7443 of 5 stars		$123.10
-0.7%		$166.15
+35.0%		-1.2%$6.99B$738.26M136.782,000
TECH
Bio-Techne
3.7974 of 5 stars		$50.79
-1.7%		$65.92
+29.8%		+9.1%$8.09B$1.21B73.613,100
A
Agilent Technologies
4.933 of 5 stars		$136.08
+0.4%		$162.79
+19.6%		+15.9%$38.30B$6.95B27.3318,100
AMN
AMN Healthcare Services
1.5524 of 5 stars		$29.47
+1.7%		$25.29
-14.2%		+41.9%$1.12B$2.73BN/A2,664

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BIO) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
OpenAI is preparing to go public
OpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...
InvestorPlace | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel